SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.

zacks.com - 2026-07-15 09:51:05

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigat

gurufocus.com - 2026-07-14 08:00:00

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificial intelligence (AI)-native biopharma company focused on advancing late-stage programs in life-threatening indications with urgent unmet medical needs. Previously, ridinilazole was evaluated in Summit's Phase III Ri-CoDIFy study for the tre.

businesswire.com - 2026-07-14 07:00:00

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

fool.com - 2026-06-30 07:45:03

Summit Therapeutics is a highly volatile, single-asset company with a binary outcome. SMMT exhibits unusually concentrated ownership and heightened short interest, creating conditions for a short squeeze to take place. Recent pullbacks, driven by mixed market receptions to events do not fundamentally alter the investment narratives, present investors with an attractive entry point ahead of key catalysts.

seekingalpha.com - 2026-06-22 09:05:03

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price, less underwriting discounts and c.

businesswire.com - 2026-06-09 16:47:00

Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-08 15:08:30

After years of lagging the market, healthcare may be taking on a new role in investor portfolios.

247wallst.com - 2026-06-07 09:30:55

Investors have bet new drugs can topple Merck's Keytruda, but the evidence so far points to something smaller.

wsj.com - 2026-06-06 05:30:00

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM ET, providing a corporate overview and update on recent progress, including the development of its innovative investigational bispecific antibody, ivonescimab. The presentatio.

businesswire.com - 2026-06-04 16:30:00

Summit Therapeutics (SMMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com - 2026-06-04 13:01:10

Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress Transcript

seekingalpha.com - 2026-06-01 13:54:03

Summit Therapeutics Inc. (NASDAQ:SMMT) stock is down on Monday following the recent announcement regarding the clinical trial results of ivonescimab on Sunday.

benzinga.com - 2026-06-01 10:56:56

The consensus price target hints at a 67.1% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

zacks.com - 2026-06-01 10:56:18

Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients ​live 15% longer than BeOne Medicines' Tevimbra immunotherapy.

reuters.com - 2026-06-01 06:34:55

Biotech companies have always licensed programs, but never so many from one region in particular.

fool.com - 2026-05-31 13:45:00

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and spons

gurufocus.com - 2026-05-31 10:00:00

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit's partner Akeso, Inc. (HKEX Code: 9926.HK), will be presented today as part of the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation is entitled “Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untrea.

businesswire.com - 2026-05-31 09:06:00

An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of Clinical Oncology annual meeting. Called ivonescimab, the bispecific antibody targets PD-1 — similar to Merck's best-selling drug Keytruda — and VEGF — similar to Roche's Avastin.

cnbc.com - 2026-05-31 08:00:02

Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in

gurufocus.com - 2026-05-30 09:00:00

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer (mCRC) co-sponsored by Summit and Akeso, featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. The data were presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation, entitle.

businesswire.com - 2026-05-30 08:00:00

Summit Therapeutics advances ivonescimab with late-stage NSCLC and CRC studies, with FDA review underway and new partnerships expanding its oncology reach.

zacks.com - 2026-05-22 10:31:23

/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody

prnewswire.com - 2026-05-18 14:22:00

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

zacks.com - 2026-05-18 13:01:22

Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.

zacks.com - 2026-05-04 14:15:18

Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA decision, and 2026 is stacked with catalysts.

247wallst.com - 2026-05-04 11:07:33

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Summit Therapeutics Inc. (NASDAQ: SMMT). The investigation focuses on Summit's executive officers and whether investor losses may be recovered under federal securities laws.

globenewswire.com - 2026-05-04 09:23:00

Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know.

benzinga.com - 2026-05-01 11:12:01

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the first quarter ended March 31, 2026. Clinical & Operational Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects ass.

businesswire.com - 2026-04-30 16:32:00

Large-cap stocks surged last week as catalysts from short squeezes to innovation-driven momentum fueled broad gains.

feeds.benzinga.com - 2026-04-19 10:01:30

Summit Therapeutics stock jumps as FDA accepts ivonescimab BLA. Strong trial data and partnerships boost confidence in its cancer therapy pipeline.

zacks.com - 2026-04-16 12:30:46